Tyrosine kinase inhibitor, masitinib, limits neuronal damage, as measured by serum neurofilament light chain concentration in a model of neuroimmune-driven neurodegenerative disease
This study is the first demonstration that masitinib, a drug that targets the innate as opposed to the adaptive neuroimmune system, can lower serum NfL levels, and by extension therefore, neuronal damage, in a neuroimmune-driven neurodegenerative disease model. Overall, findings indicate that masitinib has a neuroprotective effect under conditions of chronic neuroinflammation and therefore plausible disease-modifying activity across a broad range of neurodegenerative diseases.
Authors
- Kathleen Flosseau
- Patrick Vermersch (ORCID: https://orcid.org/0000-0003-0997-8817)
- Laurent Gros (ORCID: https://orcid.org/0000-0001-5116-2980)
- Truong-An Tran
- Olivier Hermine (ORCID: https://orcid.org/0000-0003-2574-3874)
- Lamya Loussaief
- Colin D. Mansfield (ORCID: https://orcid.org/0000-0001-9175-5051)
- Alain Moussy
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Université de Lille (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- AB Science (France) (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institut des Maladies Génétiques Imagine (FR)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1371/journal.pone.0322199
- Citations
- 1
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39